DeepMed Research

The Vanderbilt University

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Non-Myeloablative Conditioning and Bone Marrow Transplantation

Not Applicable

Active, not recruiting

Conditions: Hemoglobinopathies
Sickle Cell Disease

Interventions: Drug: Thymoglobulin
Drug: Fludarabine
Drug: Cyclophosphamide (CTX)
Drug: Mesna
Drug: Sirolimus
Drug: Mycophenolate mofetil (MMF)
Procedure: Bone marrow transplantation
Radiation: Total body irradiation

First Posted Date: 2013-05-09

Last Posted Date: 2024-01-10

Lead Sponsor: Vanderbilt-Ingram Cancer Center

Target Recruit Count: 26

Registration Number: NCT01850108

Locations: 🇺🇸
Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States
🇫🇷
Saint-Louis Hospital, Paris, France
🇬🇧
St Mary's Hospital, London, United Kingdom

BYL719 and Letrozole in Post-Menopausal Patients With Hormone Receptor-Positive Metastatic Breast Cancer

Phase 1

Active, not recruiting

Conditions: Stage IV Breast Cancer
Estrogen Receptor-positive Breast Cancer
HER2-negative Breast Cancer
Invasive Ductal Breast Carcinoma
Progesterone Receptor-positive Breast Cancer
Recurrent Breast Cancer

Interventions: Drug: PI3K inhibitor BYL719
Drug: letrozole
Other: laboratory biomarker analysis
Other: pharmacological studies

First Posted Date: 2013-02-15

Last Posted Date: 2024-07-23

Lead Sponsor: Vanderbilt-Ingram Cancer Center

Target Recruit Count: 46

Registration Number: NCT01791478

Locations: 🇺🇸
Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States
🇺🇸
Massachusetts General Hospital, Dana-Farber Cancer Institute, Boston, Massachusetts, United States

Low-Dose Acetylsalicylic Acid in Treating Patients With Stage I-III Non-Small Cell Lung Cancer

Early Phase 1

Terminated

Conditions: Adenocarcinoma of the Lung
Recurrent Non-small Cell Lung Cancer
Stage IA Non-small Cell Lung Cancer
Stage IIB Non-small Cell Lung Cancer
Stage IIIA Non-small Cell Lung Cancer
Stage IIA Non-small Cell Lung Cancer
Stage IB Non-small Cell Lung Cancer
Stage IIIB Non-small Cell Lung Cancer

Interventions: Drug: acetylsalicylic acid
Other: laboratory biomarker analysis

First Posted Date: 2012-10-16

Last Posted Date: 2020-01-14

Lead Sponsor: Vanderbilt-Ingram Cancer Center

Target Recruit Count: 4

Registration Number: NCT01707823

Locations: 🇺🇸
Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States

Dabrafenib Alone and in Combination With Trametinib Before Surgery in Treating Patients With Locally or Regionally Advanced Melanoma That Can Be Removed By Surgery

Phase 2

Terminated

Conditions: Stage IIIA Melanoma
Stage IIB Melanoma (Locally Advanced)
Recurrent Melanoma
Stage IIC Melanoma (Locally Advanced)
Stage IIIB Melanoma
Stage IIIC Melanoma
Stage IV Melanoma (Limited, Resectable)

Interventions: Drug: dabrafenib
Drug: trametinib
Other: laboratory biomarker analysis

First Posted Date: 2012-10-04

Last Posted Date: 2017-06-23

Lead Sponsor: Vanderbilt-Ingram Cancer Center

Target Recruit Count: 13

Registration Number: NCT01701037

Locations: 🇺🇸
Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States

Nashville Early Diagnosis Lung Cancer Project

Active, not recruiting

Conditions: Lung Cancer

Interventions: Procedure: Sputum sample
Procedure: Pulmonary function tests
Radiation: Computerized tomography (CT) scan of the chest
Other: Buccal epithelium collection
Procedure: Nasal brushings
Procedure: Bronchoscopy
Procedure: Bronchoalveolar lavage
Procedure: Blood sample collection
Procedure: Urine sample
Procedure: Questionnaire-data collection

First Posted Date: 2011-11-21

Last Posted Date: 2023-12-12

Lead Sponsor: Vanderbilt-Ingram Cancer Center

Target Recruit Count: 480

Registration Number: NCT01475500

Locations: 🇺🇸
Veterans Administration, Nashville, Tennessee, United States
🇺🇸
Vanderbilt University, Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States

68Ga-DOTATATE PET Scan in Neuroendocrine Cancer

Phase 2

Completed

Conditions: Neuroendocrine Carcinoma

Interventions: Radiation: 68Ga-DOTATATE PET scan

First Posted Date: 2011-07-18

Last Posted Date: 2016-03-29

Lead Sponsor: Vanderbilt-Ingram Cancer Center

Target Recruit Count: 97

Registration Number: NCT01396382

Locations: 🇺🇸
Vanderbilt University Medical Center, Nashville, Tennessee, United States

Linifanib in Treating Patients With Advanced, Refractory Colorectal Cancer

Phase 2

Terminated

Conditions: Stage IVA Colon Cancer
Stage IVA Rectal Cancer
Recurrent Colon Cancer
Recurrent Rectal Cancer
Stage IVB Colon Cancer
Stage IVB Rectal Cancer

Interventions: Drug: linifanib

First Posted Date: 2011-06-03

Last Posted Date: 2014-08-26

Lead Sponsor: Vanderbilt-Ingram Cancer Center

Target Recruit Count: 30

Registration Number: NCT01365910

Locations: 🇺🇸
Vanderbilt Cool Springs, Franklin, Tennessee, United States
🇺🇸
Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States

Biomarkers in Predicting Response in Patients With Graft-Versus-Host Disease Undergoing Extracorporeal Photophoresis

Not Applicable

Terminated

Conditions: Graft Versus Host Disease (GVHD)

Interventions: Procedure: extracorporeal photopheresis
Other: laboratory biomarker analysis

First Posted Date: 2011-03-29

Last Posted Date: 2021-01-14

Lead Sponsor: Vanderbilt-Ingram Cancer Center

Target Recruit Count: 85

Registration Number: NCT01324908

Locations: 🇺🇸
Emory University, Atlanta, Georgia, United States
🇺🇸
Dana Farber Cancer Center, Boston, Massachusetts, United States
🇺🇸
Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States

and more 1 locations

Aurora A Kinase Inhibitor MLN8237 in Treating Patients With Unresectable Stage III-IV Melanoma

Phase 2

Terminated

Conditions: Stage IIIc Melanoma
Recurrent Melanoma
Stage IV Melanoma

Interventions: Other: laboratory biomarker identification and analysis
Procedure: biopsy
Other: immunohistochemistry/tissue microarrays
Genetic: TdT-mediated dUTP nick end labeling assay
Other: mass spectrometry

First Posted Date: 2011-03-16

Last Posted Date: 2016-05-30

Lead Sponsor: Vanderbilt-Ingram Cancer Center

Target Recruit Count: 12

Registration Number: NCT01316692

Locations: 🇺🇸
Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States

Sorafenib Tosylate and Stereotactic Radiosurgery in Treating Patients With Brain Metastases

Phase 1

Completed

Conditions: Tumors Metastatic to Brain

Interventions: Drug: sorafenib tosylate
Radiation: stereotactic radiosurgery
Other: laboratory biomarker analysis

First Posted Date: 2011-01-13

Last Posted Date: 2017-07-17

Lead Sponsor: Vanderbilt-Ingram Cancer Center

Target Recruit Count: 23

Registration Number: NCT01276210

Locations: 🇺🇸
Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy